Schizophrenia Research
Volume 96, Issue 1 , Pages 87-92 , November 2007

The catechol O-methyltransferase Val158Met polymorphism is not associated with broad-based cognitive functioning in schizophrenia

  • Faith B. Dickerson

      Affiliations

    • Stanley Research Program at Sheppard Pratt, Sheppard Pratt Health System, 6501 North Charles, St., Baltimore, MD, 21204, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 410 938 4359; fax: +1 410 938 4364.
    • ,
  • John J. Boronow

      Affiliations

    • Stanley Research Program at Sheppard Pratt, Sheppard Pratt Health System, 6501 North Charles, St., Baltimore, MD, 21204, USA
    • ,
  • Cassie Stallings

      Affiliations

    • Stanley Research Program at Sheppard Pratt, Sheppard Pratt Health System, 6501 North Charles, St., Baltimore, MD, 21204, USA
    • ,
  • Andrea E. Origoni

      Affiliations

    • Stanley Research Program at Sheppard Pratt, Sheppard Pratt Health System, 6501 North Charles, St., Baltimore, MD, 21204, USA
    • ,
  • Anne Sullens

      Affiliations

    • Stanley Research Program at Sheppard Pratt, Sheppard Pratt Health System, 6501 North Charles, St., Baltimore, MD, 21204, USA
    • ,
  • Robert H. Yolken

      Affiliations

    • Stanley Neurovirology Laboratory, 600 North Wolfe St., Johns Hopkins University School of Medicine, Baltimore, MD, 21207, USA

Received 10 March 2007 ,Revised 12 May 2007 ,Accepted 16 May 2007.

References 

  1. Ayres AM, Busatto GF, Menezes PR, Schaufelberger MS, Coutinho L, Murray RM, et al. Cognitive deficits in first-episode psychosis: a population-based study in Sao Paulo, Brazil. Schizophr. Res. 2007;90(1–3):338–343
  2. Bilder RM, Volavka J, Czobor P, Malhotra AK, Kennedy JL, Ni X, et al. Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol. Psychiatry. 2002;52(7):701–707(Oct 1)
  3. Burdick KE, Lencz T, Funke B, Finn CT, Szeszko PR, Kane JM, et al. Genetic variation in DTNBP1 influences general cognitive ability. Hum. Mol. Genet. 2006;15(10):1563–1568
  4. Dickerson FB, Boronow JJ, Stallings C, Origoni AE, Ruslanova I, Yolken RH. Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia. Arch. Gen. Psychiatry. 2003;60(5):466–472
  5. Dickerson FB, Boronow JJ, Stallings C, Origoni AE, Cole S, Leister F, et al. The catechol O-methyltransferase Val158Met polymorphism and herpes simplex virus type 1 infection are risk factors for cognitive impairment in bipolar disorder: additive gene–environmental effects in a complex human psychiatric disorder. Bipolar Disord. 2006;8(2):124–132
  6. Dickerson F, Boronow J, Stallings C, Origoni A, Yolken R. The lymphotoxin Cys13Arg polymorphism and cognitive functioning in individuals with schizophrenia. Schizophr. Res. 2007;89(1–3):173–176
  7. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzsanti CM, Straub RE, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2001;98(12):6917–6922
  8. Egan MF, Straub RE, Goldberg TE, Yakub I, Callicott JH, Hariri AR, et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2004;101(34):12604–12609
  9. Ehlis AC, Reif A, Herrmann MJ, Lesch KP, Fallgatter AJ. Impact of catechol-O-methyltransferase on prefrontal brain functioning in schizophrenia spectrum disorders. Neuropsychopharmacology. 2007;32(1):162–170
  10. Goldberg TE, Egan MF, Gscheidle T, Coppola R, Weickert T, Kolachana BS, et al. Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch. Gen. Psychiatry. 2003;60(9):889–896
  11. Goldberg TE, Straub RE, Callicott JH, Hariri A, Mattay VS, Bigelow L, et al. The G72/G30 gene complex and cognitive abnormalities in schizophrenia. Neuropsychopharmacology. 2006;31(9):2022–2032
  12. Golimbet V, Gritsenko I, Alfimova M, Lebedeva I, Lezheiko T, Abramova L, et al. Association study of COMT gene Val158Met polymorphism with auditory P300 and performance on neurocognitive tests in patients with schizophrenia and their relatives. World J. Biol. Psychiatry. 2006;7(4):238–245
  13. Harvey PD. Cognitive and functional effects of atypical antipsychotic medications. J. Clin. Psychiatry. 2006;67(10):e13
  14. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12(3):426–445
  15. Hennah W, Thomson P, Peltonen L, Porteous D. Genes and schizophrenia: beyond schizophrenia: the role of DISC1 in major mental illness. Schizophr. Bull. 2006;32(3):409–416
  16. Hilbe J. Sample size determination for means and proportions. Stata Tech. Bull. 1993;11:17–20
  17. Ho BC, Wassink TH, O'Leary DS, Sheffield VC, Andreasen NC. Catechol-O-methyl transferase Val158Met gene polymorphism in schizophrenia: working memory, frontal lobe MRI morphology and frontal cerebral blood flow. Mol. Psychiatry. 2005;10(3):229,287–229,298
  18. Ho BC, Milev P, O'Leary DS, Librant A, Andreasen NC, Wassink TH. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch. Gen. Psychiatry. 2006;63(7):731–740
  19. Hobart MP, Goldberg R, Bartko JJ, Gold JM. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia II. Convergent/discriminant validity and diagnostic groups comparisons. Am. J. Psychiatry. 1999;156(12):1951–1957
  20. Hori H, Noguchi H, Hashimoto R, Nakabayashi T, Omori M, Takahashi S, et al. Antipsychotic medication and cognitive function in schizophrenia. Schizophr. Res. 2006;86(1–3):138–146
  21. Kay SR. Positive and Negative Syndromes in Schizophrenia: Assessment and Research. New York: Bruner/Mazel; 1991;
  22. Kerns JG, Berenbaum H. Cognitive impairments associated with formal thought disorder in people with schizophrenia. J. Abnorm. Psychology. 2002;111(2):211–224
  23. Leung A, Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr. Scand., Suppl. 2000;401:3–38
  24. Manning V, Wanigaratne S, Best D, Strathdee G, Schrover I, Gossop M. Screening for cognitive functioning in psychiatric outpatients with schizophrenia, alcohol dependence, and dual diagnosis. Schizophr. Res. 2007;91(1–3):151–158(Mar)
  25. Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol. Psychiatry. 2004;55(10):1013–1022
  26. Randolph C. RBANS Manual — Repeatable Battery for the Assessment of Neuropsychological Status. San Antonio, TX: Psychological Corporation; 1998;
  27. Rosa A, Peralta V, Cuesta MJ, Zarzuela A, Serrano F, Martinez-Larrea A, et al. New evidence of association between COMT gene and prefrontal neurocognitive function in healthy individuals from sibling pairs discordant for psychosis. Am. J. Psychiatry. 2004;161(6):1110–1112
  28. Rujescu D, Meisenzahl EM, Krejcova S, Giegling I, Zetzsche T, Reiser M, et al. Plexin B3 is genetically associated with verbal performance and white matter volume in human brain. Mol. Psychiatry. 2007;12(2):190–194
  29. Szekeres G, Keri S, Juhasz A, Rimanoczy A, Szendi I, Czimmer C, et al. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2004;24(1):1–5
  30. Szoke A, Schurhoff F, Meary A, Mathieu F, Chevalier F, Trandafir A, et al. Lack of influence of COMT and NET genes variants on executive functions in schizophrenic and bipolar patients, their first-degree relatives and controls. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2006;141(5):504–512
  31. van Winkel R, Myin-Germeys I, Delespaul P, Peuskens J, De Hert M, van Os J. Premorbid IQ as a predictor for the course of IQ in first onset patients with schizophrenia: a 10-year follow-up study. Schizophr. Res. 2006;88(1–3):47–54
  32. Wassink TH, Nopoulos P, Pietila J, Crowe RR, Andreasen NC. NOTCH4 and the frontal lobe in schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2003;118(1):1–7
  33. White T, Ho BC, Ward J, O'Leary D, Andreasen NC. Neuropsychological performance in first-episode adolescents with schizophrenia: a comparison with first-episode adults and adolescent control subjects. Biol. Psychiatry. 2006;60(5):463–471
  34. Wilk CM, Gold JM, Bartko JJ, Dickerson F, Fenton WS, Knable M, et al. Test–retest stability of the repeatable battery for the assessment of neuropsychological status in schizophrenia. Am. J. Psychiatry. 2002;159(5):838–844
  35. Woodward ND, Jayathilake K, Meltzer HY. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr. Res. 2007;90(1–3):86–96
  36. Yue W, Kang G, Zhang Y, Qu M, Tang F, Han Y, et al. Association of DAOA polymorphisms with schizophrenia and clinical symptoms or therapeutic effects. Neurosci. Lett. 2007;416(1):96–100(Apr 6)

PII: S0920-9964(07)00235-6

doi: 10.1016/j.schres.2007.05.021

Schizophrenia Research
Volume 96, Issue 1 , Pages 87-92 , November 2007

Article Tools